TB-500 Side Effects: What the Research Reports

Is TB-500 Safe? Safety Data in the Literature

The available safety data for thymosin beta-4 and TB-500 derives from Phase I human trials of the full-length 44-amino-acid protein, animal model studies, and in vitro experiments. No published randomized controlled trial has evaluated the safety profile of the TB-500 heptapeptide (Ac-LKKTETQ) in humans specifically.

In the Ruff et al. (2010) Phase I randomized, placebo-controlled study of intravenous thymosin beta-4 in healthy human volunteers, doses from 42 to 1,260 mg were administered — a dose range far in excess of informal human protocols — and no dose-limiting toxicities or serious adverse events were observed ^[11]. Adverse events were infrequent and characterized as mild to moderate. The pharmacokinetic profile showed dose-proportional responses with a short plasma half-life of 0.95–2.1 hours ^[11].

A separate Phase I trial of recombinant human thymosin beta-4 (NL005) in healthy Chinese volunteers confirmed this profile across single and multiple daily doses: no serious adverse events, no accumulation after 10 consecutive daily doses, and a minimal anti-drug antibody rate (1/108 single-dose subjects; 1/28 multiple-dose subjects, both resolved at follow-up) ^[12]. The investigators concluded the compound supports continued development for acute myocardial infarction ^[12].

These data apply to the full-length thymosin beta-4 protein administered intravenously — not to the shorter TB-500 heptapeptide administered subcutaneously or intramuscularly. The safety profile of the heptapeptide via subcutaneous or intramuscular routes in humans has not been established in published clinical trials.

Adverse Events Reported in TB-500 Studies

From the published and clinical-adjacent record, the adverse events associated with thymosin beta-4 and TB-500 include:

Injection-site reactions. Redness, swelling, and discomfort at the site of injection are the most commonly reported events in informal human reports; these are consistent with any peptide injection and are not specific to TB-500's pharmacology.

Transient systemic reactions. Fatigue, mild nausea, and dizziness have been described in informal human contexts. In Phase I IV administration of full-length Tβ4 at doses up to 1,260 mg, adverse events were mild to moderate with no dose-limiting events ^[11].

No observed serious adverse events. Neither of the two published Phase I trials of thymosin beta-4 in humans observed serious adverse events or dose-limiting toxicities ^[11][12].

Long-term safety of TB-500 in humans is not established; the published human trials were acute or short-term Phase I safety studies, not multi-year observational studies.

Theoretical Risks: Angiogenesis and Oncological Considerations

The principal theoretical risk associated with TB-500's pro-angiogenic mechanism is a potential oncological concern: angiogenesis supports tumor growth and metastasis, and a compound that upregulates VEGF and drives new vessel formation could theoretically promote the progression of an undetected or pre-existing neoplasm.

No completed animal carcinogenicity study has demonstrated this risk for thymosin beta-4 or TB-500 specifically. The theoretical concern derives from mechanistic reasoning — pro-angiogenic compounds are generally considered cautiously in oncology contexts — not from observed tumor-promoting events in the published literature ^[6][7]. The in vitro and in vivo cardiac studies reviewed above, including the porcine MI model at therapeutic doses, reported no increase in tumor formation ^[16].

This does not mean the risk is absent; it means the carcinogenicity question has not been formally resolved in published controlled studies. Anyone considering TB-500 use in a clinical or research context would need to weigh this theoretical risk against the absence of carcinogenicity data.

TB-500 WADA Status and Regulatory Context

TB-500 is prohibited at all times under the WADA Prohibited List, Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. The prohibition applies to both thymosin beta-4 and the TB-500 heptapeptide fragment ^[1]. Athletes subject to WADA-compliant anti-doping testing who use TB-500 face a potential 2–4 year suspension.

The WADA detection window is approximately 30–45 days post-administration for urine and blood samples analyzed by LC-MS/MS in accredited laboratories ^[1]. This reflects metabolite accumulation and tissue distribution, not active plasma half-life. The 2012 Ho et al. study established the validated analytical method for detecting Ac-LKKTETQ and its metabolites in equine matrices ^[1]; this method underlies WADA-accredited anti-doping screening.

TB-500 is not FDA-approved for any human indication. Full-length thymosin beta-4 has been investigated by RegeneRx Biopharmaceuticals under IND for cardiac and corneal indications; the TB-500 heptapeptide fragment is listed in ClinicalTrials.gov under NCT07487363 without published results as of this writing.